NCT06943365View on ClinicalTrials.gov

Role of Anti-TREK-1 Autoantibodies in SCVF

Enrolling by invitationOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2028

Conditions
Short-coupled Ventricular FibrillationIdiopathic Ventricular Fibrillation
Interventions
OTHER

Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies

Semiquantitative measure of circulating anti-TREK-1 autoantibodies in plasma of study participants using a peptid microarray

GENETIC

DPP6 risk haplotype

Systematic genetic screening for the Dutch DPP6 risk haplotype in all study participants and correlation of results with the presence or absence of anti-TREK-1 autoantibodies

Trial Locations (1)

G1V4G5

Institut universitaire de cardiologie et pneumologie de Québec, Québec

All Listed Sponsors
lead

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

OTHER